Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Events Timeline

(ET)

2026-03-02

08:10:00

Monopar Therapeutics Appoints Susan Rodriguez as Chief Commercial and Strategy Officer

2025-11-13 (ET)

2025-11-13

08:02:27

Monopar Therapeutics Announces Quarterly EPS of 48 Cents, Exceeding Consensus Estimate of 40 Cents

2025-11-09 (ET)

2025-11-09

13:31:07

Monopar unveils fresh data and analyses from the Phase 2 ALXN1840-WD-204 study

News

6.0

01-09CNBC

Goldman Sachs Cuts Netflix Price Target to $112 Ahead of Earnings

7.5

2025-12-31Benzinga

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

5.0

2025-12-29NASDAQ.COM

Monopar CFO Vu Acquires 1,500 Shares of MNPR for $104,925

6.0

2025-11-14Benzinga

Home Depot Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday

6.0

2025-11-13Benzinga

Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics with $100 Price Target Intact

6.0

2025-11-10Benzinga

Chardan Capital Reaffirms Buy Rating on Monopar Therapeutics and Increases Price Target to $100

11 Analyst Rating

Wall Street analysts forecast MNPR stock price to rise

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

95.00

Averages

112.91

High

130.00

Current: 0.000

Low

95.00

Averages

112.91

High

130.00

Morgan Stanley

Maxwell Skor

Overweight

initiated

$115

AI Analysis

2026-01-09

Reason

Morgan Stanley

Maxwell Skor

Price Target

$115

AI Analysis

2026-01-09

initiated

Overweight

Reason

Morgan Stanley analyst Maxwell Skor initiated coverage of Monopar Therapeutics with an Overweight rating and $115 price target. The firm says ALXN1840 demonstrated "meaningful" copper mobilization and neurological benefit in a Phase 3 study as a "differentiated therapy" for Wilson's disease with a once-daily profile. The analyst sees an "encouraging set-up" for the shares.

Raymond James

Christopher Raymond

Strong Buy -> Outperform

downgrade

$142 -> $123

2025-11-14

Reason

Raymond James

Christopher Raymond

Price Target

$142 -> $123

2025-11-14

downgrade

Strong Buy -> Outperform

Reason

Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm's key opinion leader feedback indicates a "heavier commercial" lift than first imagined for Monopar in Wilson disease. A " higher risk premium to our estimates is warranted here," the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MNPR

Unlock Now

Valuation Metrics

The current forward P/E ratio for Monopar Therapeutics Inc (MNPR.O) is -22.16, compared to its 5-year average forward P/E of -6.33. For a more detailed relative valuation and DCF analysis to assess Monopar Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.33

Current PE

-22.16

Overvalued PE

1.03

Undervalued PE

-13.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding MNPR

RA Capital Management, L.P.

Deep Track Capital, LP

TCG Crossover Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Monopar Therapeutics Inc (MNPR) stock price today?

The current price of MNPR is 53.47 USD — it has decreased -2.44

What is Monopar Therapeutics Inc (MNPR)'s business?

What is the price predicton of MNPR Stock?

Wall Street analysts forecast MNPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNPR is112.91 USD with a low forecast of 95.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Monopar Therapeutics Inc (MNPR)'s revenue for the last quarter?

Monopar Therapeutics Inc revenue for the last quarter amounts to -4.09M USD, increased 159.89

What is Monopar Therapeutics Inc (MNPR)'s earnings per share (EPS) for the last quarter?

Monopar Therapeutics Inc. EPS for the last quarter amounts to -2090534.00 USD, increased 94.74

How many employees does Monopar Therapeutics Inc (MNPR). have?

Monopar Therapeutics Inc (MNPR) has 16 emplpoyees as of March 03 2026.

What is Monopar Therapeutics Inc (MNPR) market cap?

Today MNPR has the market capitalization of 357.32M USD.

MNPR Overview

MNPR Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding MNPR

Trading Trends

People Also Watch

Frequently Asked Questions

What is Monopar Therapeutics Inc (MNPR) stock price today?

What is Monopar Therapeutics Inc (MNPR)'s business?

What is the price predicton of MNPR Stock?

What is Monopar Therapeutics Inc (MNPR)'s revenue for the last quarter?

What is Monopar Therapeutics Inc (MNPR)'s earnings per share (EPS) for the last quarter?

How many employees does Monopar Therapeutics Inc (MNPR). have?

What is Monopar Therapeutics Inc (MNPR) market cap?